

CURRICULUM VITAE

TANJA MILOSAVLJEVIC, M.Sc., Ph.D.

Current Title: Instructor - Research

Business Address: LSU Health New Orleans, School of Medicine, Department of Surgery, 533 Bolivar St, CSRB729, New Orleans, LA 70112, US.

Business Telephone and Fax: phone: 504-568-6876; fax: 504-568-2202.

Business email Address: tmilos@lsuhsc.edu.

Citizenship: Citizen of Republic of Serbia

Permanent resident of United States of America (green card)

EDUCATION:

Undergraduate:

- **B.Sc. in Molecular Biology and Physiology** (GPA 9.48)
University of Belgrade, Faculty of Biology, Belgrade, Republic of Serbia
(October 1989-August 1993)

Graduate/Medical:

- **M.Sc. in Molecular Biology**
University of Belgrade, Faculty of Biology, Belgrade, Republic of Serbia
(October 1993-April 1996)
- **Ph.D. in Molecular Biology**
University of Belgrade, Faculty of Biology, Belgrade, Republic of Serbia
(June 1996-December 2000)

Post-Doctoral Fellowships:

- **HEC-EGIDE/Eiffel Scholarship for post-doctoral studies** (August 2001-August 2002)
Department of Cell Cycle and Myogenesis, Institute for Human Genetics, Montpellier, France
- **Postdoctoral Fellow** (June 2004-December 2006)
Department of Pharmacology and Experimental Therapeutics, Louisiana State University (LSU) Health New Orleans, LA, US

Other (i.e. JD, MPH, MBA, MHA, Career Development Courses):

- **Serbian Ministry for Science and Technology M.Sc. fellowship** (January 1994-April 1996)
Molecular Biology Laboratory, IBISS, Belgrade, Republic of Serbia

EDUCATIONAL TRAINING

- Cancer Epigenetics: Environmental Influences and Molecular Mechanisms (Houston, TX, 2015)
- National Carcinoid & NET Patient Conference (New Orleans, LA, 2014, 2016, 2018)
- NIH Regional workshop on program funding and grant administration (New Orleans, LA, 2017)
- Mindfulness for better health workshop (New Orleans, LA, 2017)
- NANETS New Orleans Regional Neuroendocrine Tumor (NET) Education: The Multidisciplinary Management of NET Cancers (New Orleans, LA, 2018)
- The Socratic method (New Orleans, LA, 2018)
- Becoming a Successful Leader (Inclusive Leadership Training, edX, 2019)

Academic, Professional, and Research Appointments:

1. **Research Scientist** (December 2000-August 2001)
Molecular Biology Laboratory, Institute for Biological Research "Sinisa Stankovic" (IBISS), Belgrade, Republic of Serbia
2. **Postdoctoral Fellow** (August 2001-August 2002)
Department of Cell Cycle and Myogenesis, Institute for Human Genetics (IGH), Montpellier, France
3. **Research Scientist** (September 2002-May 2004)
Molecular Biology Laboratory, Belgrade, IBISS, Republic of Serbia
4. **Postdoctoral Fellow** (June 2004-December 2006)
Department of Pharmacology and Experimental Therapeutics, LSU Health New Orleans, LA, US
5. **Postdoctoral Researcher** (2007-August 2008)
Department of Biochemistry and Molecular Biology, LSU Health New Orleans, LA, US
6. **Senior Postdoctoral Researcher** (September 2008-November 2015)
Department of Surgery, LSU Health New Orleans, LA, US
7. **Instructor - Research** (December 2015-present)
Department of Surgery, LSU Health New Orleans, LA, US
8. **Clinical Trial Coordinator** (July 2021-present)
Department of Surgery, LSU Health New Orleans, LA, US

TEACHING EXPERIENCE AND RESPONSIBILITIES

Undergraduate, Medical, or Graduate Students (trained in molecular biology/biochemistry techniques):

- **Undergraduate:** Peter Casey, Steven Lipani, Adrienne Reeks, Sheradie Jackson, Amira Karagic, Ariana Dirige, Clarke Allen, Pearl Watson, Alana Williams, Joel Epling, Jaclyn Mehrez, Bailey Gentile
- **Post-baccalaureate:** Elise Juge.
- **Medical students:** Zacchary Keats, Russ Guidry
- **Surgical residents:** Michael Hall, Jennifer Owen

RESEARCH AND SCHOLARSHIP

Grants and Contracts:

1. **NIH grant:** *Combinatorial signaling through MEK1.* (2004-2006)
Role in the project: postdoctoral fellow
 - Aim: Understand mechanisms underlying inappropriate cell motility during metastasis. Development of this project relied on daily interaction and collaboration with a large group of multidisciplinary scientists within LSU Cell Adhesion and Migration Group.
 - Training in techniques for studying protein-protein interactions and RNA interference.
2. **NIH grant:** *The mechanisms of action of Nischarin in tumor cell migration and invasion.* (2007-2008)
Role in the project: postdoctoral researcher
 - Completed experiments and participated in manuscript preparation.
 - Data published in one manuscript and presented in two poster presentations.
3. **Pennington Biomedical Research Pilot Grant:** *Modulation of angiogenic gene expression by black raspberry (BR) extract.* (2011-2012)
Role in the project: senior postdoctoral researcher
 - Performed gene expression experiments, data interpretation, and identified candidate BR-response genes in vein.
 - Created and presented interim and final project reports. Gene expression validation was not possible due to sample loss caused by equipment failure.
 - Data presented at two meetings (local and national).
4. **Angiogenic Switch project (LSU Health Foundation New Orleans):** *"Define molecular signature responsible for angiogenic switch" - (2009-2021/ 2021-2022)*
Role in the project: Co-Investigator/ PI
 - Developed a novel protocol for harvesting neovessels from patient-derived tissues (placental vein, inferior vena cava, and neuroendocrine tumors) embedded in 3D matrix (patented Human Vein angiogenesis Assay) and obtaining high quality RNA for gene expression studies.
 - Defined the molecular signature responsible for angiogenic switch.
 - Data presented at two local meetings and one manuscript (*in preparation*)

5. **Human Neuroendocrine Tumors (NETs) project (LSU Health Foundation New Orleans/ private donors):** (2009-2021/ 2021-2022)

Role in the project: Co-investigator/ PI

- Liaison clinical laboratory staff with Neuroendocrine Cancer experts and oversaw tumor specimens (collection, processing, banking and analysis) and equipment (acquisition, maintenance) for the only exclusively Neuroendocrine Tumor repository (~1,400 specimens/ ~1200 patients) in US.
- Directed testing of effect of pharmacological compounds (i.e. RTKs, tubulin inhibitors, peptides, growth factors, etc.) and botanicals (black raspberry, gallic acid, etc.) on blood vessel growth of human NETs. Test results were used to direct therapy in NET patients with metastatic disease (personalized cancer patient care).
- Conducted on-site training (technical, scientific) of personnel about usage of instruments, clinical utility of laboratory/diagnostic tests, provided in-service education as needed, and ensured compliance with all applicable certification standards and regulations.
- Manuscript preparation/ submission and grant application process
- Data presented at eighteen meetings (local, national and international), abstracts (five published), and manuscripts.

6. **NET DRP SPORE grant:** "*Development of Shared NET PDX Repository*". (2016-2017)

Role in the project: Co-investigator

- Collaborated with Neuroendocrine Tumor group (Holden Comprehensive Cancer Center, University of Iowa) on developing NET PDX from cryopreserved LSU NET specimens.
- Managed NET repository and established physical sample and data sharing between LSU Health New Orleans and University of Iowa.

7. **LSU Health New Orleans, School of Medicine, Department of Surgery:** "*Validation of Screening Modality to Diagnose Neuroendocrine Tumors (NETs) of the Gut*" (2017-2021)

Role in the project: Co-investigator

- Aim: Design and development of innovative diagnostic test for rapid at-home and Point-of-Care early detection of rare neuroendocrine tumors
- Define small bowel NETs genetic profile (RNA expression, DNA methylation pattern tumor vs normal), and evaluate whether methylation pattern can be used to identify patients with small bowel NET

8. **LSU Foundation project:** "*Robert & Kay Watson Biomarker Discovery & Treatment Research*" (2018-2021)

Role in the project: Co-investigator

- Whole-exome (Tempus xE panel, DNA) and full transcriptome (RNA) sequencing of NETs (n=96) with the goal of better understanding the molecular composition of

NET patients and how their genomic profile relates to therapy, response and outcome.

9. **Clinical Trials:**

Clinical Trial 1: “A Prospective, Double-Blinded, Randomized Controlled Trial of Dehydrated Human Amniotic-Chorionic Membrane for Incisional Hernia Prophylaxis” Sponsor: LSUHSC (2021-2022)

Role in the project: Clinical Trial Coordinator

- Supported clinical trial study activities and collaborated with clinicians on all study activities: subject eligibility assessment for the study (EMR review, screening interviews, and discussions with physicians), development and implementation of recruitment plan, subject enrollment and follow-up in accordance with the research safety protocols. Data collection and storage in a HIPAA-compliant database (REDCap)
- Maintained study-related documentation in accordance with site and sponsor compliance requirements.

Clinical Trial 2: “A Multicenter Registry Study of Avance Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair (RANGER)” Sponsor: AXOGEN (2021-2022)

Role in the project: Clinical Trial Coordinator

- Maintained source study documents (annual IRB, informed consent forms, HIPAA forms, routine monitoring visits and site closure procedure).

Funded applications:

1. **LSU “Leverage Innovation for Technology Transfer (LIFT2) Fund:** “*Development of novel screening method for neuroendocrine tumors of the gut*” (2019-2021)

Role in the project: Co-investigator

- Development of a non-invasive screening tool for an early detection of NETs

Not-funded applications:

1. **Botanical Dietary Supplements Research Center 2016-17 Pilot Project Program Award:** “*Black raspberry-gene interactions in adult human inferior vena cava as indicators of metabolic dysfunction (i.e. diabetes mellitus)*”

Role in the project: PI

2. **LSU Health New Orleans, School of Medicine, Research Enhancement Program, Clinical research Grant Program:** “*Development of novel screening method for neuroendocrine tumors of the gut*” (2017)

Role in the project: Co-investigator

3. **LSU Health New Orleans, School of Medicine, Research Enhancement Program, New Project Application (2017): "Black raspberry - gene interactions in human vascular endothelium: prevention and treatment of diabetic retinopathy" (2017)**
Role in the project: Co-investigator

Journal Publications:

Refereed

1. Grigorov I, Bogojevic D, **Milosavljevic T**, Sekularac S, Petrovic M. Characterization of P 29 involved in the regulation of haptoglobin gene expression in rat liver during acute phase response. *Jugoslav Med Biohemija-Yugoslav Med Biochem.* 1996;15(4):311-312.
2. Sekularac S, Grigorov I, Petrovic M, Bogojevic D, **Milosavljevic T**, Sevaljevic L. Regulation of transcription of rat haptoglobin gene in acute inflammation - characterization of carbohydrate moiety of transcription factor P70. *Jugoslav Med Biohemija-Yugoslav Med Biochem.* 1996;15(4):308-308.
3. Petrovic M, Grigorov I, **Milosavljevic T**, Sekularac S, Bogojevic D. The role of rat liver nucleoproteins in transcriptional regulation of rat haptoglobin and alpha(2)-macroglobulin genes during the acute-phase reaction. *Jugoslav Med Biohemija-Yugoslav Med Biochem.* 1996;15(4):311-311.
4. Petrovic M, Grigorov I, Milosavljevic T, Bogojevic D, Sekularac S, Sevaljevic L. Structural and functional homology between the 29 kD rat liver nucleoprotein and the high mobility group 1 protein. *Mol Biol Rep.* 1996;23(2):79-85. doi: 10.1007/BF00424433.
5. Petrovic M, Grigorov I, **Milosavljevic T**, Bogojevic D. The DNA binding affinity of rat liver nucleoproteins to the alpha(1)-acid glycoprotein gene. *Biochem Mol Biol Int.* 1996;40(4):741-749.
6. **Milosavljevic T**, Grigorov I, Bogojevic D, Sekularac S, Petrovic M. The acute phase-dependant increase in binding affinity of rat liver nucleoproteins to the hormone regulatory element of haptoglobin gene. *Jugoslav Med Biohemija-Yugoslav Med Biochem.* 1996;15(4):310-310.
7. Bogojevic D, Grigorov I, Sekularac S, **Milosavljevic T**, Petrovic M. Acute phase-related changes in binding affinity of foetal liver nucleoproteins to regulatory elements of alpha(2)-macroglobulin, alpha(1)-acid glycoprotein and haptoglobin gene. *Jugoslav Med Biohemija-Yugoslav Med Biochem.* 1996;15(4):309-309.
8. Grigorov I, **Milosavljevic T**, Petrovic M. Acute-phase induced phosphorylation of rat liver nucleoprotein p70 modulates its binding affinity for the haptoglobin gene. *Biochem Mol Biol Int.* 1998;45(5):1067-1072.
9. Grigorov I, **Milosavljevic T**, Cvetkovic I, Petrovic M. Participation of two isoforms of C/EBP beta transcription factor in the acute-phase regulation of the rat haptoglobin gene. *Cell Biol Int.* 1998;22(9-10):685-693. doi: 10.1006/cbir.1998.0307.
10. Grigorov I, Lazic T, Cvetkovic I, **Milosavljevic T**, Petrovic M. STAT3 involvement in the acute phase-related expression of the rat haptoglobin gene. *Mol Biol Rep.* 2000;27(2):81-86. doi: 10.1023/A:1007177605135.
11. Grigorov I, **Milosavljevic T**, Cvetkovic I, Petrovic M. HMG-1 as regulatory trans-acting protein in the acute phase-induced expression of the rat liver haptoglobin gene. *Gen Physiol Biophys.* 2001;20(4):401-412.

12. Grigorov I, Lazic T, Cvetkovic I, **Milosavljevic T**, Petrovic M. Opposite nuclear level and binding activity of STAT5B and STAT3 proteins with rat haptoglobin gene under normal and turpentine induced acute phase conditions. *Mol Biol Rep.* 2001;28(4):217-222. doi: 10.1023/A:1015749109119.
13. **Milosavljevic TS**, Petrovic MV, Cvetkovic ID, Grigorov II. DNA binding activity of C/EBP beta and C/EBP delta for the rat alpha(2)-macroglobulin gene promoter is regulated in an acute-phase dependent manner. *Biochemistry (Moscow)*;67(8):918-26.
14. **Milosavljevic T**, Lazic T, Uskokovic A, Petrovic M, Grigorov I. Expression of the rat liver haptoglobin gene is mediated by isoforms of C/EBP alpha, -beta and -delta proteins. *Gen Physiol Biophys.* 2003;22(2):181-190.
15. Grigorov I, **Milosavljevic T**, Ilic M, et al. The effect of chronic food restriction on liver acute phase protein response in female and male wistar rats. *Acta Vet -Beogr.* 2004;54(1):13-20. doi: 10.2298/AVB0401013G.
16. Grigorov I, Cvetkovic I, **Milosavljevic T**, et al. The effect of O-GlcNAc glycosylation of rat liver nucleoproteins on their acute phase-dependent binding ability to the hormone responsive element of the haptoglobin gene. *Gen Physiol Biophys.* 2004;23(3):367-374.
17. Ding Y, **Milosavljevic T**, Alahari SK. Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. *Mol Cell Biol.* 2008;28(11):3742-3756. doi: 10.1128/MCB.01832-07.

Published Abstracts

1. Hall M, **Milosavljevic T**, Casey P, Anthony CT, Woltering EA. Somatostatin receptor subtypes 1-5 gene expression differs in multiple sites in the same individual. *Ann Surg Oncol.* 2012;19:S53-S53.
2. **Milosavljevic T**, Guidry RM Jr, Juge EN, Woltering EA. The effect of Erlotinib treatment on human angiogenesis. *Cancer Research* 76(14) Tumor biology:3279-3279, Abstract 3279, July 2016 (2016). doi: 10.1158/1538-7445.AM2016-3279.
3. Juge EN, **Milosavljevic T**, Casey P, Hall M, Woltering EA. The effect of Dovitinib on angiogenesis in human neuroendocrine tumors. *Cancer Research* 77(15) Endocrinology:1799-1799, Abstract 1799, July (2016). doi: 10.1158/1538-7445.AM2016-1799.
4. **Milosavljevic T**, Chouest EJ, Anthony CE, Dirige A, Wang YZ, Boudreaux JP, Ramcharan T, Woltering EA. *In vitro* screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors *Cancer Research* 77(13), Tumor biology:780-780, Abstract 780, July (2017). doi: 10.1158/1538-7445.AM2017-780.
5. Kaemmer C, Howe J, Galbraith J, Galbraith J, Knudson C, Darbro B, **Milosavljevic T**, Woltering E, Wen K-K, Wu M, Quelle D. Developing model systems of neuroendocrine tumors: Cell lines and patient-derived xenograft (PDX) tumors. *Pancreas.* 2018;47(3):343.

Manuscripts in Preparation

1. **Milosavljevic T**, Chouest EJ, Zabaleta J, Anthony CA, Fang Z, Woltering EA. Novel model systems for studying the angiogenic switch in the human placental vein and inferior vena cava
2. **Milosavljevic T**, Chouest EJ, Zabaleta J, Hall M, Del Valle L, Boudreaux JP, Wang YZ, Anthony CA, Woltering EA. Angiogenic gene expression in primary neuroendocrine tumors and their metastases.

3. **Milosavljevic T**, Chouest EJ, Reeks AM, Owens JA, Wang YZ, Boudreaux JP, Eugene A Woltering. In vitro screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors [Dovitinib lactate, Regorafenib, Erlotinib, Imatinib, Vatalanib, and Sunitinib].
4. Mehrez J, Gentile B, Skill NJ, **Milosavljevic T**, Chouest EJ, Maluccio MA, Bren-Mattison Y, Elliott H, and Woltering EA. Black Raspberry Extract Modulates Angiogenic Proteome Linked to Neuroendocrine Cancer.

Scientific Presentations

Local Posters

1. **Milosavljevic T**, Walch A, Baranwal S, Alahari SK. The integrin-binding protein Nischarin interacts with tumor suppressor LKB1 in breast cancer. Graduate School Research Day, LSU Health Sciences Center, New Orleans, LA, US (2008).
2. Lipani S, **Milosavljevic T**, Woltering EA. Valproic acid's effect on Notch gene expression in neuroendocrine tumors of the liver. Short-term Research experiences in Cancer. Stanley Scott Cancer Center-LSUHSC, New Orleans, LA and NCI, US (2012).
3. Casey PM, **Milosavljevic T**, Woltering EA. The effect of dovitinib on human angiogenesis. Short-term Research experiences in Cancer. Stanley Scott Cancer Center-LSUHSC, New Orleans, LA and NCI, US (2012).
4. **Milosavljevic T**, Anthony, CT, Casey PM, Juge EN, Zabaleta, J, Woltering EA, Black Raspberry Extract Modulates Angiogenic Gene Expression. Louisiana Cancer Research Consortium Retreat 2014; New Orleans, LA, US (2014).
5. Juge EN, **Milosavljevic T**, Reeks AM, Owens JA, Woltering EA. Regorafenib (Stivarga) Effectively Inhibits Angiogenesis in Neuroendocrine Tumors. Louisiana Cancer Research Consortium Retreat 2014; New Orleans, LA, US (2014).
6. Guidry, R, Juge EN, **Milosavljevic T**, Woltering, EA. The effect of Erlotinib on Human Angiogenesis. Short-term Research experiences in Cancer. Stanley Scott Cancer Center-LSUHSC, New Orleans, LA and NCI, US (2015).
7. Juge EN, **Milosavljevic T**, Boudreaux JP, Wang YZ, Woltering EA. Dovitinib Effectively Inhibits Angiogenesis in Neuroendocrine Tumors, Louisiana Cancer Research Consortium Retreat 2015; New Orleans, LA, US (2015).
8. **Milosavljevic T**, Juge EN, Zabaleta, J, Hall MA, Boudreaux, JP, Wang, YZ, Woltering EA. Angiogenic Gene Expression in Primary Neuroendocrine Tumors and Their Metastases. Louisiana Cancer Research Consortium Retreat 2015; New Orleans, LA, US (2015).
9. **Milosavljevic T**, Chouest EJ, Zabaleta J, Anthony CE, Woltering EA. Two novel model systems for studying the angiogenic switch *in vitro*. 4th Annual LA Conference on Computational Biology & Bioinformatics, New Orleans, LA, US (2016).
10. **Milosavljevic T**, Chouest EJ, Zabaleta J, Anthony CE, Woltering EA. The novel human vein model systems for studying the angiogenic switch *in vitro*. Louisiana Cancer Research Consortium Retreat 2016, New Orleans, LA, US (2016).
11. **Milosavljevic T**, Chouest EJ, Anthony CE, Dirige A, Wang YZ, Boudreaux JP, Ramcharan T, Woltering EA. *In vitro* screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors. Louisiana Cancer Research Consortium Retreat 2017, New Orleans, LA, US (2017).
12. **Milosavljevic T**, Hall M, Del Valle, L, Juge EN, Zabaleta, J, Boudreaux, JP, Wang YZ, Anthony CT, Woltering EA. Angiogenic gene expression in primary and

- metastatic neuroendocrine tumors. 5th Annual LA Conference on Computational Biology & Bioinformatics, New Orleans, LA, US (2017).
13. **Milosavljevic T**, Allen CM, Chouest E, Woltering EA. The effect of natural compounds on angiogenesis in human inferior vena cava. Louisiana Cancer Research Consortium Retreat 2017, New Orleans, LA, US (2018).
 14. **Milosavljevic T**, Chouest EJ, Zabaleta J, Woltering EA. Gene expression analysis of physiologic angiogenesis over time. Louisiana Cancer Research Consortium Retreat, Molecular Signaling, New Orleans, LA, US (2019).
 15. Gentile B, **Milosavljevic T**, Chouest E, Gabra M, Mamikunian P, Eugene A. Woltering. Development of early-detection test for neuroendocrine tumor in stool. Louisiana Cancer Research Consortium Retreat, Clinical and Translational Research, New Orleans, LA, US (2020).
 16. Mehrez J, Gentile B, **Milosavljevic T**, Chouest E, Eugene A. Woltering. In vitro model system for intact, human cancer analysis of phenotypic angiogenesis and gene expression. Louisiana Cancer Research Consortium Retreat, Cancer Genetics, New Orleans, LA, US (2020).

National Posters

1. Wang YF, Lavezzi TS, **Milosavljevic T**, Walch AN, Baranwal S, Alahari SK. MicroRNA Profiling of Human Breast Cancer Cell Line MDA-MB-231 (sub line 4175) and MCF10A. 47th Annual American Society for Cell Biology meeting. Washington, DC, US (2007).
2. Hall MA, **Milosavljevic T**, Casey P, Anthony CT, Woltering EA. Somatostatin Receptor Subtypes 1-5 Gene Expression Differs in Multiple Sites In the Same Individual. Society of Surgical Oncology, 65th Annual Cancer Symposium. Orlando, FL, US (2012).
3. Hall MA, **Milosavljevic T**, Casey P, Juge E, Anthony CT, Wood KC, Woltering EA. Anti-angiogenic effect of Dovitinib in Neuroendocrine Tumors over-expressing the FGFR3 gene. American College of Surgeons 2013 Clinical Congress, Washington DC, US (2013).
4. **Milosavljevic T**, Anthony CT, Casey PM, Juge EN and Woltering EA. Modulation of angiogenic gene expression by Black Raspberry extract. American Institute of Cancer research, Annual research Conference. Food, Nutrition, Physical activity and cancer, Bethesda, MD, US (2013).
5. **Milosavljevic T**, Hall M, Del Valle, L, Juge EN, Zabaleta, J, Boudreaux, JP, Wang, YZ, Catherine T. Anthony, Woltering EA. Angiogenic gene expression in primary neuroendocrine tumors and their metastases. American Society of Clinical Oncology Annual Meeting, San Francisco, CA, US (2016).
6. **Milosavljevic T**, Juge EN, Reeks AM, Owens JO, Wang YZ, Boudreaux JP, Woltering EA. Effect of Regorafenib on Angiogenesis in Neuroendocrine Tumors *in vitro*. American Society of Clinical Oncology Annual Meeting, San Francisco, CA, US (2016).
7. **Milosavljevic T**, Guidry RM Jr, Juge EN, Woltering EA. The effect of Erlotinib treatment on human angiogenesis. American Association of Cancer Research Annual Meeting, New Orleans, LA, US (2016).
8. Juge EN, **Milosavljevic T**, Casey P, Hall M, Woltering EA. The effect of Dovitinib on angiogenesis in human neuroendocrine tumors. American Association of Cancer Research Annual Meeting, New Orleans, LA, US (2016).
9. Beyer DT, Chouest EJ, **Milosavljevic T**, Wang YZ, Thiagarajan R, Ramirez RA, Campeau RJ, Boudreaux JP, Ricks MJ, Woltering EA. In-Vitro Evaluation of

- Angiogenesis Does Not Correlate with the Survival of Neuroendocrine Tumors. American College of Surgeons Clinical Congress, Washington DC, US (2016).
10. **Milosavljevic T**, Chouest EJ, Anthony CE, Dirige A, Wang YZ, Boudreaux JP, Ramcharan T, Woltering EA. *In vitro* screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors American Association of Cancer Research Annual Meeting, Washington, DC, US (2017).
 11. Chouest E, **Milosavljevic T**, Zabaleta J, Woltering E. Gene Expression Regulation of Human Physiologic Angiogenesis Over Time Angiogenesis, Gordon Research Seminar: Molecular and Cellular Dynamics of Endothelial Cells in Health and Disease (Conferee ID: 1419074), Newport, RI, US (2019). *Awarded presentation*
 12. Skill N, Campbell E, **Milosavljevic T**, Chouest E, Voros E, Woltering E, Maluccio M. Liquid biopsy metabolomic profiling of Neuroendocrine cancer patients. 12th Annual North American Neuroendocrine Tumor Society Symposium (B-20), Boston, MA, US (2019).
 13. Mehrez J, Gentile B, Skill N, **Milosavljevic T**, Chouest E, Maluccio MA, Woltering E. Mapping anti-angiogenic proteome associated with black raspberry and gallic acid treatment in neuroendocrine cancer. 13th Annual North American Neuroendocrine Tumor Society Virtual Symposium (2020).

International Posters

1. Hall MA, **Milosavljevic T**, Casey P, Anthony, CT, Woltering EA. Somatostatin Receptor Subtypes 1-5 Gene Expression Differs in Multiple Sites From the Same Individual. The 14th International symposium on Anti-Angiogenic therapy. La Jolla, California, US (2012).
2. Kaemmer C, Howe J, Galbraith J, Knudson C, Darbro B, **Milosavljevic T**, Woltering E, Wen K-K, Wu M, Quelle D. Developing Model Systems of Neuroendocrine Tumors: Cell Lines and Patient-Derived Xenograft (PDX) Tumors 10th Annual North American Neuroendocrine Tumor Society Symposium, Philadelphia, PA, US (2017).

SERVICE ACTIVITIES

Special assignments – ad hoc task forces/working groups, projects, etc.:

1. *Judged presentations at AACR Undergraduate Student Caucus & Poster Competition* - 11th (New Orleans, LA, US, 2016) and 12th (Washington DC, VA, US, 2017) Annual AACR Meeting
2. *Mentored students* - “The conquest of cancer and the next generation of cancer researchers” program about education and research - 11th (New Orleans, LA, US, 2016) and 12th (Washington DC, VA, US, 2017) Annual AACR Meeting

Administrative Responsibilities:

Departmental:

Clinical Trials and Research studies administration - prepared essential study documents (annual IRB, protocols, informed consent, HIPAA forms, enrolment logs, CRFs, site monitoring visits, and study closure) for two clinical trials and seven clinical research studies.

Clinical Trials:

1. "A Prospective, Double-Blinded, Randomized Controlled Trial of Dehydrated Human Amniotic-Chorionic Membrane for Incisional Hernia Prophylaxis" (PI: Dr Frank Lau, Sponsor: LSUHSC)
2. "A Multicenter Registry Study of Avance Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair (RANGER)" (PI: Dr Frank Lau, Sponsor: AXOGEN)

Clinical Research Studies:

1. "A study of human tumor angiogenesis using a fibrin-thrombin clot model" (PI: Dr. Woltering)
2. "Inhibition of angiogenesis using the human placental vein model" (PI: Dr. Dr. Woltering)
3. Organotypic culture of human tissue" (PI: Dr Frank Lau)
4. Developing novel three-dimensional model systems for investigating liposarcoma microenvironment in tumor development (PI: Dr Frank Lau)
5. "Limb Salvage through Tissue Engineering: A Novel Treatment Modality using Dehydrated Human Amnion/Chorion Membrane" (PI: Dr Frank Lau)
6. "Cutis Graft for Hernia Repair" (PI: Dr Ian Hodgdon)
7. "Efficacy of Short Chain Fatty Acid Infusion on Human Xenograft Tumor Model" (PI: Dr Ian Hodgdon)

Community Service Activities:

- Volunteered in non-profit Young Leadership Council community project to reactivate youth training programs in the Central City neighborhood of New Orleans in the aftermath of Hurricane Katrina (2006).